[1] [1] Lheureux S, Gourley C, Vergote I, et al. Epithelial ovarian cancer[J]. Lancet, 2019, 393(10177): 1240-1253.

[2] [2] Bartoletti M, Musacchio L, Giannone G, et al. Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors[J]. Cancer Treat Rev, 2021, 101: 102298.

[3] [3] LaFargue CJ, Dal Molin GZ, Sood AK, et al. Exploring and comparing adverse events between PARP inhibitors[J]. Lancet Oncol, 2019, 20(1): e15-e28.

[4] [4] Xiao Y, Bi M, Guo H, et al. Multi-omics approaches for biomarker discovery in early ovarian cancer diagnosis[J]. EBioMedicine, 2022, 79: 104001.

[5] [5] Feng W, Dean DC, Hornicek FJ, et al. Exosomes promote pre-metastatic niche formation in ovarian cancer[J]. Mol Cancer, 2019, 18(1): 124.

[7] [7] Wang H, Cao R, Xia L, et al. Purification and functional characterization of a histone H3-lysine 4-specific methyltransferase[J]. Mol Cell, 2001, 8(6): 1207-1217.

[8] [8] Batista IAA, Helguero LA. Biological processes and signal transduction pathways regulated by the protein methyltransferase SETD7 and their significance in cancer[J]. Signal Transduct Target Ther, 2018, 3: 19.

[9] [9] Monteiro FL, Williams C, Helguero LA. A systematic review to define the multi-faceted of lysine methyltrans-ferase SETD7 in cancer[J]. Cancers(Basel), 2022, 14(6): 1414.

[10] [10] Zhao K, Li Y, Han T, et al. Comparison of the expression levels of lysine-specific demethylase 1 and survival outcomes between triple-negative and non-triple-negative breast cancer[J]. Oncol Lett, 2021, 21(2): 102.

[11] [11] Si W, Zhou J, Zhao Y, et al. SET7/9 promotes multiple malignant processes in breast cancer development via RUNX2 activation and is negatively regulated by TRIM21[J]. Cell Death Dis, 2020, 11(2): 151.

[12] [12] Huang R, Li X, Yu Y, et al. SETD7 is a prognosis predicting factor of breast cancer and regulates redox homeostasis[J]. Oncotarget, 2017, 8(55): 94080-94090.

[13] [13] Duan B, Bai J, Qiu J, et al. Histone-lysine N-methyltransferase SETD7 is a potential serum biomarker for colorectal cancer patients[J]. EBioMedicine, 2018, 37: 134-143.

[14] [14] Akiyama Y, Koda Y, Byeon SJ, et al. Reduced expression of SET7/9, a histone mono-methyltransferase, is assocociated with gastric cancer progression[J]. Oncotarget, 2016, 7(4): 3966-3983.

[15] [15] Zhou J, Xie M, Shi Y, et al. MicroRNA-153 functions as a tumor suppressor by targeting SET7 and ZEB2 in ovarian cancer cells[J]. Oncol Rep, 2015, 34(1): 111-120.

[16] [16] Yang X, Bai Q, Chen W, et al. m6A-dependent modulation via IGF2BP3/MCM5/Notch axis promotes partial EMT and LUAD metastasis[J]. Adv Sci(Weinh), 2023, 10(20): e2206744.

[17] [17] Loret N, Denys H, Tummers P, et al. The role of epithelial-to-mesenchymal plasticity in ovarian cancer progression and therapy resistance[J]. Cancers(Basel), 2019, 11(6): 838.

[18] [18] Chiang C, Yang H, Zhu L, et al. The epigenetic regulation of nonhistone proteins by SETD7: new targets in cancer[J]. Front Genet, 2022, 13: 918509.

[19] [19] Gu Y, Wang X, Liu H, et al. SET7/9 promotes hepatocellular carcinoma progression through regulation of E2F1[J]. Oncol Rep, 2018, 40(4): 1863-1874.

[20] [20] Gao L, Zhang J, Long Q, et al. SETD7 promotes metastasis of triple-negative breast cancer by YY1 lysine methylation[J]. Biochim Biophys Acta Mol Basis Dis, 2023, 1869(7): 166780.